10-K: Klotho Neurosciences Secures $2.17 Million in Convertible Note Financing

Klotho Neurosciences enters into a securities purchase agreement for \$2.17 million via senior convertible notes and warrants to fund general corporate purposes.

Summary

• Klotho Neurosciences, Inc. has entered into a Securities Purchase Agreement for \$2,173,914 through senior convertible notes and warrants.
• The financing involves the issuance of senior convertible notes and warrants to purchase common stock.
• The initial closing included a note for \$1,086,957 and a warrant for 2,000,000 shares, with a purchase price of \$1,000,000.
• A second closing is possible, subject to certain conditions, for an additional note and warrant.
• The notes bear interest at 7% per annum and have an 8% original issue discount.
• Conversion of the notes into common stock is priced at \$0.25 per share, subject to certain adjustments and ownership limitations.
• The warrants are exercisable at \$0.50 per share, also subject to adjustments and ownership limitations.
• The company is obligated to seek stockholder approval to waive the Exchange Cap, which limits the number of shares issuable.
• Proceeds from the sale of the notes will be used for general corporate purposes.

Sentiment

Score: 6

Explanation: The announcement is neutral. While securing financing is generally positive, the terms include potential dilution and restrictions, balancing the positive and negative aspects.

Positives

• The financing provides Klotho Neurosciences with additional capital for general corporate purposes.
• The structure includes warrants, potentially providing additional capital to the company upon exercise.
• The company retains flexibility in the use of proceeds, allowing it to allocate capital to its most promising projects.

Negatives

• The issuance of convertible notes and warrants will dilute existing shareholders' equity.
• The company is obligated to seek stockholder approval to waive the Exchange Cap, which may not be obtained.
• The company is subject to various covenants and restrictions as part of the financing agreement.

Risks

• Failure to obtain stockholder approval for the Exchange Cap could limit the company's ability to issue shares upon conversion or exercise.
• The company's financial condition and operating results could be negatively impacted by the additional debt and interest expense.
• The company's ability to meet its obligations under the financing agreement is subject to various risks and uncertainties.

Future Outlook

The company plans to use the proceeds for general corporate purposes and is obligated to seek stockholder approval to waive the Exchange Cap. The second closing is contingent upon certain conditions being met.

Industry Context

This type of financing is common for small biotechnology companies seeking to raise capital for research and development. The use of convertible notes and warrants allows investors to participate in the potential upside of the company while providing the company with needed capital.

Comparison to Industry Standards

• Convertible notes and warrants are frequently used financing tools in the biotechnology industry, especially for companies in early stages of development.
• Comparable companies often use similar structures to raise capital, balancing the need for funding with the potential dilution to existing shareholders.
• The specific terms of the financing, such as interest rates, conversion prices, and warrant coverage, are typically negotiated based on the company's financial condition, market conditions, and investor demand.

Stakeholder Impact

• Shareholders will experience potential dilution due to the issuance of convertible notes and warrants.
• The company's ability to execute its business plan will be enhanced by the additional capital.
• The company's long-term success will depend on its ability to effectively deploy the proceeds and achieve its strategic goals.

Next Steps

• The company must seek stockholder approval to waive the Exchange Cap.
• The company must meet certain conditions to enable the second closing.
• The company must file a registration statement with the SEC to register the shares of Common Stock issuable upon conversion of the Notes or exercise of the Warrants.

Key Dates

Keywords

convertible notes, warrants, financing, capital raise, securities purchase agreement, dilution, stockholder approval, Klotho Neurosciences, general corporate purposes